FTC Says "Orange Book" Abuse Blocks Drug Competition
By Kelly Lienhard · November 14, 2022, 6:46 PM EST
The Federal Trade Commission urged a Delaware federal court to remove a patent for narcolepsy drug distribution from federal regulators' list of approved drugs and the patents covering them, arguing the patent was improperly included and...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login